- Home
- IMAX vs DYN Comparison
IMAX vs DYN Comparison
Compare IMAX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMAX | DYN |
|---|---|---|
| Founded | 1967 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IMAX | DYN |
|---|---|---|
| Price | $51.72 | $15.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $56.58 | $35.73 |
| AVG Volume (30 Days) | 1.1M | ★ 3.1M |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $410,212,000.00 | N/A |
| Revenue This Year | $13.14 | N/A |
| Revenue Next Year | $4.97 | N/A |
| P/E Ratio | $145.51 | ★ N/A |
| Revenue Growth | ★ 16.47 | N/A |
| 52 Week Low | $30.74 | $13.88 |
| 52 Week High | $57.73 | $27.31 |
Technical Indicators
Market Signals| Indicator | IMAX | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 33.38 |
| Support Level | $50.03 | $14.34 |
| Resistance Level | $55.57 | $19.54 |
| Average True Range (ATR) | 2.12 | 0.75 |
| MACD | -0.48 | 0.31 |
| Stochastic Oscillator | 36.30 | 40.25 |
Price Performance
Historical ComparisonAbout IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.